




RealRate

PHARMACEUTICAL 2017

ImmunoCellular Therapeutics Ltd.
Rank 260 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

ImmunoCellular Therapeutics Ltd. Rank 260 of 313

The relative strengths and weaknesses of ImmunoCellular Therapeutics Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoCellular Therapeutics Ltd. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 121% points. The greatest weakness of ImmunoCellular Therapeutics Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 294% points.

The company's Economic Capital Ratio, given in the ranking table, is -600%, being 183% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	13,415
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,239
Liabilities, Non-Current	0
Other Assets	3,365
Other Compr. Net Income	0
Other Expenses	1,810
Other Liabilities	7,519
Other Net Income	3,837
Property and Equipment	110
Research and Development	19,106
Revenues	0
Selling, General and Administrative Expense	5,006

Output Variable	Value in 1000 USD
Assets	16,890
Liabilities	10,758
Expenses	25,922
Stockholders Equity	6,132
Net Income	-22,086
Comprehensive Net Income	-22,086
Economic Capital Ratio	-600%

